Document Detail

Levosimendan for low cardiac output: a pediatric experience.
MedLine Citation:
PMID:  16672640     Owner:  NLM     Status:  MEDLINE    
This was a retrospective observational study in a pediatric intensive care unit, in which 19 patients received levosimendan. There were no adverse events attributable to levosimendan and no instances where the clinical condition worsened after administration. Arterial lactate levels decreased significantly following levosimendan administration during cardiopulmonary bypass for anticipated low cardiac output. In those with established low cardiac output, trends toward improved hemodynamics were seen, with heart rate reduction, an increase in mean blood pressure, a reduction in arterial lactate, and reduced conventional inotrope use. Levosimendan was safely used in a small number of pediatric patients with established low cardiac output state who demonstrated improved hemodynamics and tissue perfusion, with a tendency to reduced conventional inotrope usage, and this warrants its evaluation as an inotrope in the pediatric population.
Jonathan R Egan; Andrew J B Clarke; Stephen Williams; Andrew D Cole; Julian Ayer; Stephen Jacobe; Richard B Chard; David S Winlaw
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of intensive care medicine     Volume:  21     ISSN:  0885-0666     ISO Abbreviation:  J Intensive Care Med     Publication Date:    2006 May-Jun
Date Detail:
Created Date:  2006-05-04     Completed Date:  2006-08-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8610344     Medline TA:  J Intensive Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  183-7     Citation Subset:  IM    
Pediatric Intensive Care Unit, Children's Hospital at Westmead, Sydney, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiac Output, Low / drug therapy*,  etiology
Cardiotonic Agents / administration & dosage,  pharmacology,  therapeutic use*
Child, Preschool
Drug Toxicity
Heart Defects, Congenital / complications,  drug therapy*
Hemodynamics / drug effects
Hydrazones / administration & dosage,  pharmacology,  therapeutic use*
Infant, Newborn
Infusions, Intravenous
Pyridazines / administration & dosage,  pharmacology,  therapeutic use*
Retrospective Studies
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The changing epidemiology of mechanical ventilation: a population-based study.
Next Document:  The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z...